In a large population of people with type 1 diabetes, the glycaemic target might not be achieved despite insulin therapy and issues around recurrent severe hypoglycaemia caused by insulin excess can result in irreversible neurological damage or even death.1 Clinical trials with allogeneic2 and terminally differentiated autologous3,4 stem cell-derived islets have provided convincing evidence that such therapies can restore durable normoglycaemic islet function in people with type 1 and type 2 diabetes.
The Lancet Diabetes & Endocrinology published a clinical update in Research Highlights on 26 Feb 2026.
The item focuses on Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic β-cell function pretransplant.
Review the original article for the full source wording and details.